Understanding How Data Triangulation Identifies Acute Toxicity of Novel Psychoactive Drugs
Journal of Medical Toxicology, 05/31/2012Wood DM et al.
Over the last decade, there has been an increase in the availability and use of novel psychoactive substances. There is limited information available on the potential acute toxicity (harms) associated with the use of these novel psychoactive substances. Gold standard evidence, such as animal studies or human clinical trials, is rarely available to users or healthcare professionals. However, it is possible to use triangulation of data on the acute toxicity from multiple sources to describe the overall pattern of toxicity associated with a novel psychoactive substance.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.